Mediamedic/LinkedIn
Oct 4, 2025, 12:30
Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 10:45Federica Fogacci: Co-Moderating at CA Meet 2026 in Padua – Elevating Lifestyle Interventions in Cardiology
-
Oct 10, 2026, 10:40Juan Cristóbal Morales Muñoz: Pharmacokinetic Profiling of Factor VIII Concentrates in Chilean Patients
-
Oct 10, 2026, 10:32Randall Schaefer: When Your Prehospital Agency Reports Blood Product Wastage Rates, What is it Really Reporting?
-
Oct 10, 2026, 10:26Simone Strasser: ROTEM-Guided Transfusion Cuts Blood Product Use in Patients with Cirrhosis
-
Oct 10, 2026, 10:18Jérôme S.: WHO Launches Global Roadmap to Combat Hypertensive Disorders of Pregnancy
-
Oct 10, 2026, 10:07Maha Othman: Look Forward to an Amazing ISTH 2027 in Vancouver!
-
Oct 10, 2026, 10:02Rucha Patil: National Convening Highlights Opportunities for Equitable Hemophilia Care Across India
-
Oct 10, 2026, 09:52Yuria Ito: Should Ferritin Testing Become a Routine Part of Prenatal Care in Japan?
-
Oct 10, 2026, 09:48Ahmed Alotaibi: Can We “Remove” the ABO Problem from Group O Platelets?